Acquired Thrombophilia Assay via Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods lack a specific functional test for differentiating acquired thrombotic disorders, which are a major life-threatening clinical problem, and existing thrombophilic tests are costly and labor-intensive, hindering practical clinical application.
Innovation Solution
A method involving the incubation of primary healthy blood cells with patient serum, with and without a complement inhibitor, to detect tissue factor expression, indicating the presence of an acquired thrombophilia disorder by comparing coagulation rates in both conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If specific functional tests are developed for acquired thrombotic disorders, then diagnostic precision is improved, but device complexity and cost increase
Solution Approach 1:
The diagnostic approach is segmented into distinct functional components: (1) exposure of blood cells to patient serum, (2) inhibition of complement system with specific inhibitors, (3) measurement of tissue factor expression, and (4) calculation of thrombophilic risk scores. This segmentation allows each component to be optimized independently while maintaining overall diagnostic precision.
Solution Approach 2:
Complement inhibitors serve as intermediary substances that selectively block the complement system's contribution to thrombosis. By introducing these intermediaries, the assay can isolate and measure specific pathological mechanisms without requiring complex direct detection methods, thereby improving diagnostic precision while controlling complexity.
2Measurement precision
If comprehensive thrombophilic testing is performed, then measurement precision is improved, but loss of time and productivity decrease
Solution Approach 1:
The assay performs preliminary actions by pre-exposing blood cells to patient serum and complement inhibitors before the actual measurement. This preliminary incubation phase allows the biological interactions to occur in advance, so that the subsequent tissue factor expression measurement can be completed rapidly, reducing overall testing time while maintaining comprehensive diagnostic accuracy.
Solution Approach 2:
The methodology changes key parameters from measuring multiple separate coagulation factors to measuring a single endpoint parameter (tissue factor expression) that reflects the integrated effect of multiple thrombophilic mechanisms. This parameter transformation enables comprehensive assessment with reduced testing time and increased productivity.
3Measurement precision
If multiple coagulation factors are measured, then measurement precision is improved, but device complexity and cost increase
Solution Approach 1:
The assay employs a universal detection method (tissue factor expression measurement) that can assess multiple thrombophilic mechanisms simultaneously. Instead of requiring separate tests for different coagulation factors, this multi-functional approach uses a single measurement endpoint to evaluate the overall thrombophilic state, thereby improving detection accuracy while reducing technological complexity and cost.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a cost-effective and efficient differential diagnosis for acquired thrombophilia disorders, specifically identifying acquired thrombophilia by assessing tissue factor induction in healthy cells exposed to patient serum with and without complement inhibition, effectively distinguishing it from inherited hypercoagulable diseases.
Implementation Method 1
the serum further comprises a complement inhibitor
Implementation Method 2
detecting the presence of tissue factor in the first incubation condition and in the second incubation condition
Data Source
AI summary
A method for assessing the presence of an acquired thrombophilia disorder in a patient exhibiting hypercoagulation is disclosed.